Not all SERMs are created equal

Menopause

Volumn 13, Issue 3, 2006, Pages 325-327

  Goldstein, Steven R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CENTCHROMAN; IDOXIFENE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; INFLAMMATION; LEG CRAMP; LEUKORRHEA; OSTEOPOROSIS; THROMBOSIS; URGE INCONTINENCE; UTERUS PROLAPSE;

FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PYRROLIDINES; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 33745259890     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000222332.31101.42     Document Type: Editorial

References (21)

1. McClung M, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386.
2. Goldstein SR. Unusual ultrasound appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-451.
3. Berliere M, Charles A, Galant C, Piette PH, Marbaix E, Donnex J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000;36:S35-S36.
4. Barrett-Connor E, Cauley JA, Kulkami PM, Sashegvi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004;19:1270-1275.
5. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103.
6. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-134.
7. Goldstein SR, Nanavati N. Adverse events associated with the selective estrogen modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521-527.
8. Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999;18:503-512.
9. Ke HZ, Paralkar VM, Grasser WA, et al. Nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068-2076.
10. Chesnut, 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276.
11. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
12. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
13. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.
14. Martino S, Cauley JA, Barrett-Connor E, et al, CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1731-1733.
15. Davidson M, Moffett A, Welty F, et al. Extraskeletal effects of lasofoxifene on postmenopausal women. Presented at the American Society Bone and Mineral Research, Nashville, TN, September 2005.
16. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Int 1995;87:670-675.
17. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA). Menopause 2004;11:LB-41.
18. Simon J, Gass M, Kagan R, Spino C, Nemmeth MA. Lasofoxifene effectively treats dyspareunia in postmenopausal women with vaginal atrophy. Obstet Gynecol 2005;105(Suppl 4):A3423.
19. Bachmann G, Gass M, Moffett A, Portman D, Symons J. Lasofoxifene improves symptoms associated with vaginal atrophy [Abstract]. Menopause 2004;11:669.
20. Gass M, Portman D, Bachmann G, Moffett A, Symons J. Clinical signs of vaginal atrophy are improved by SERM. the, lasofoxifene [Abstract]. Menopause 2004;11:670.
21. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.